Intellectual Property

Parcell Laboratories has a robust intellectual property portfolio that includes the ownership of worldwide exclusive rights to all aspects of the ELA stem cell platform technology, providing the company with a major commercial advantage and long-term protection across all technologies developed around the ELA cell.

Parcell’s patents include compositions-of-matter patents, manufacturing process patents covering the isolation, purification and expansion of ELA cells and method of use patents covering all of the Company’s products under development and clinical product offerings.

There are provisions under the Patient Protection and Health Care Affordability Act in the United States that could potentially extend commercial exclusivity for the Company’s cell therapy products in the United States well beyond initial patent expiration dates.

Parcell Laboratories is committed to the ongoing development and expansion of its intellectual property portfolio.